Biocon Biologics

Biocon Biologics is a subsidiary of Biocon Ltd.Biocon Biologics is committed to developing high-quality, affordable biosimilars with the aim of expanding patient access to cutting-edge therapies worldwide. It holds a unique position globally as a fully integrated "pure-play" biosimilar organization. Biocon Biologics aspires to transform patients' lives through innovative and inclusive healthcare solutions. The company boasts an extensive portfolio of biosimilar products in global clinical development, three of which have been commercialized in developed markets such as Europe, Australia, the United States, and Japan. Biocon Biologics' pipeline includes 28 molecules, including 11 molecules in collaboration with Mylan, several in partnership with Sandoz, and many being independently developed. As a leading global producer of insulin, it has over 15 years of experience in meeting the needs of diabetes patients and has delivered more than 2 billion doses of recombinant human insulin (rh-insulin) worldwide to date. To ensure universal access to high-quality insulin, it offers nasal insulin at less than 10 cents per day for direct government procurement in low- and middle-income countries.